Por favor, use este identificador para citar o enlazar este ítem:
https://www.arca.fiocruz.br/handle/icict/27760
Tipo
ArtículoDerechos de autor
Acceso abierto
Colecciones
Metadatos
Mostrar el registro completo del ítem
RATIONAL ZIKA VACCINE DESIGN VIA THE MODULATION OF ANTIGEN MEMBRANE ANCHORS IN CHIMPANZEE ADENOVIRAL VECTORS
Autor
López-Camacho, César
Abbink, Peter
Larocca, Rafael A.
Dejnirattisai, Wanwisa
Boyd, Michael
Badamchi-Zadeh, Alex
Wallace, Zoë R.
Doig, Jennifer
Velazquez, Ricardo Sanchez
Neto, Roberto Dias Lins
Coelho, Danilo F.
Kim, Young Chan
Donald, Claire L.
Owsianka, Ania
De Lorenzo, Giuditta
Kohl, Alain
Gilbert, Sarah C.
Dorrell, Lucy
Mongkolsapaya, Juthathip
Patel, Arvind H.
Screaton, Gavin R.
Barouch, Dan H.
Hill, Adrian V. S.
Reyes-Sandoval, Arturo
Abbink, Peter
Larocca, Rafael A.
Dejnirattisai, Wanwisa
Boyd, Michael
Badamchi-Zadeh, Alex
Wallace, Zoë R.
Doig, Jennifer
Velazquez, Ricardo Sanchez
Neto, Roberto Dias Lins
Coelho, Danilo F.
Kim, Young Chan
Donald, Claire L.
Owsianka, Ania
De Lorenzo, Giuditta
Kohl, Alain
Gilbert, Sarah C.
Dorrell, Lucy
Mongkolsapaya, Juthathip
Patel, Arvind H.
Screaton, Gavin R.
Barouch, Dan H.
Hill, Adrian V. S.
Reyes-Sandoval, Arturo
Afiliación
Múltipla - ver em Notas
Resumen en ingles
Zika virus (ZIKV) emerged on a global scale and no licensed vaccine ensures long-lasting anti-ZIKV immunity. Here we report the design and comparative evaluation of four replication-deficient chimpanzee adenoviral (ChAdOx1) ZIKV vaccine candidates comprising the addition or deletion of precursor membrane (prM) and envelope, with or without its transmembrane domain (TM). A single, non-adjuvanted vaccination of ChAdOx1 ZIKV vaccines elicits suitable levels of protective responses in mice challenged with ZIKV. ChAdOx1 prME ∆TM encoding prM and envelope without TM provides 100% protection, as well as long-lasting anti-envelope immune responses and no evidence of in vitro antibody-dependent enhancement to dengue virus. Deletion of prM and addition of TM reduces protective efficacy and yields lower anti-envelope responses. Our finding that immunity against ZIKV can be enhanced by modulating antigen membrane anchoring highlights important parameters in the design of viral vectored ZIKV vaccines to support further clinical assessments.
Compartir